Evidence map›Paper›PMID 23992036›Full record

ArticleJournal of neurochemistry2013

Long-term nicotine treatment down-regulates α6β2* nicotinic receptor expression and function in nucleus accumbens.

Xiomara A Perez, J Michael McIntosh, Maryka Quik

Open access · greenAbstract read
In one paragraph

Article in Journal of neurochemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Rodent models for nicotine withdrawal.Journal of psychopharmacology (Oxford, England) · 2021
    Review
  3. Review
  4. Review
  5. The striatal cholinergic system in L-dopa-induced dyskinesias.Journal of neural transmission (Vienna, Austria : 1996) · 2018
    Review
  6. Article
  7. Article
  8. Review
  9. Chronic Nicotine Mitigates Aberrant Inhibitory Motor Learning Induced by Motor Experience under Dopamine Deficiency.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2016
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Xiomara A PerezCenter for Health Sciences, SRI International, Menlo Park, CA, USA.
J Michael McIntosh
Maryka Quik
SRI International · USUniversity of Utah · US

Funding

Venoms, Biological Resources, Molecular BiologyP01GM048677 · NIGMS · UNIVERSITY OF UTAH · PI BANDYOPADHYAY, PRADIP K · 1993 to 2018
$32.2M
Mechanisms of nicotine-mediated decrease in L-dopa induced-dyskinesiasR01NS059910 · NINDS · SRI INTERNATIONAL · PI QUIK, MARYKA · 2009 to 2013
$3.7M
Novel nAChR-Targeted PeptidesR01GM103801 · NIGMS · UNIVERSITY OF UTAH · PI MCINTOSH, J MICHAEL · 2012 to 2019
$2.4M
NIGMS NIH HHS GM103801NIGMS NIH HHS GM48677NIGMS NIH HHS P01 GM048677NIGMS NIH HHS R01 GM103801NINDS NIH HHS NS59910NINDS NIH HHS R01 NS059910
6 · The paper itself

Abstract

Long-term nicotine exposure induces alterations in dopamine transmission in nucleus accumbens that sustain the reinforcing effects of smoking. One approach to understand the adaptive changes that arise involves measurement of endogenous dopamine release using voltammetry. We therefore treated rats for 2-3 months with nicotine and examined alterations in nAChR subtype expression and electrically evoked dopamine release in rat nucleus accumbens shell, a region key in addiction. Long-term nicotine treatment selectively decreased stimulated α6β2* nAChR-mediated dopamine release compared with vehicle-treated rats. It also reduced α6β2* nAChRs, suggesting the receptor decline may contribute to the functional loss. This decreased response in release after chronic nicotine treatment was still partially sensitive to the agonist nicotine. Studies with an acetylcholinesterase inhibitor demonstrated that the response was also sensitive to increased endogenous acetylcholine. However, unlike the agonists, nAChR antagonists decreased dopamine release only in vehicle- but not nicotine-treated rats. As antagonists function by blocking the action of acetylcholine, their ineffectiveness suggests that reduced acetylcholine levels partly underlie the dampened α6β2* nAChR-mediated function in nicotine-treated rats. As long-term nicotine modifies dopamine release by decreasing α6β2* nAChRs and their function, these data suggest that interventions that target this subtype may be useful for treating nicotine dependence. Long-term nicotine treatment decreases dopamine (DA) transmission in the mesolimbic dopaminergic system. Our data suggest this may involve a decrease in α6β2* nicotinic receptor expression and function. These changes may play a key role in nicotine reward and dependence.

Indexed as

Ambenonium ChlorideAnimalsCholinesterase InhibitorsDopamineDopamine Plasma Membrane Transport ProteinsDown-RegulationElectric StimulationMaleNicotineNicotinic AgonistsNicotinic AntagonistsNucleus AccumbensRatsRats, Sprague-DawleyReceptors, NicotinicTime Factorsalpha6beta2 nicotinic acetylcholine receptorAmbenonium ChlorideCholinesterase InhibitorsDopamineDopamine Plasma Membrane Transport ProteinsNicotineNicotinic AgonistsNicotinic AntagonistsReceptors, Nicotinicaddictionnicotinenicotinic receptorsnucleus accumbensvoltammetry

Identifiers

PMID23992036
PMCPMC3859710
OpenAlexW1980714446

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.